Fate Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
0.0%projected annual EPS growth
Analyst Coverage
9analysts covering
FY EPS (est.)
-$1.04next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 10 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Short-Term Investments Quarterly174.8MTarget: Sufficient to fund operations into 2028
Quarterly Operating Expenses Quarterly34.3MTarget: Maintain disciplined spending under $35M per quarter
FT819 Autoimmune Disease Patient Enrollment Quarterly27.0Target: Complete Phase 1 cohort and expand outpatient treatment
Watch Items
- Initiation of Phase 2 RECLAIM-LN trial for FT819 in lupus nephritisTrigger: First patient dosed in 2H 2026Action: Verify clinical trial site activation and patient screening progress
- FDA CDRP (CMC Development and Readiness Pilot) program milestonesTrigger: Alignment on CMC readiness for accelerated clinical timelinesAction: Monitor regulatory updates regarding manufacturing scale-up and BLA readiness
- FT836 Phase 1 solid tumor clinical data updatesTrigger: Presentation of expanded cohort data at upcoming medical conferencesAction: Evaluate safety, tolerability, and lesion reduction without conditioning chemotherapy
Research as of 19 Jun 2026